Zanchetti A
Istituto di Clinica Medica e Terapia Medica, Università di Milano, Italy.
J Hypertens Suppl. 1996 Sep;14(2):S77-80; discussion S80-1. doi: 10.1097/00004872-199609002-00015.
Several ongoing trials are investigating the anti-atherosclerotic effects of antihypertensive drugs in hypertensive patients. Changes in carotid intimal-medial thicknesses and atherosclerotic plaques are being explored by a sensitive quantitative B-mode ultrasound technique. MULTICENTER ISRADIPINE/DIURETIC ATHEROSCLEROSIS STUDY (MIDAS): The results from this pioneering study indicated a slower progression, at least in the first 6 months, of carotid plaques in isradipine-treated patients than in diuretic-treated patients. MIDAS has been particularly valuable in giving information on the rate of growth of intimal-medial thickness in hypertensive patients and on the best end-point to use in carotid ultrasound trials. EUROPEAN LACIDIPINE STUDY ON ATHEROSCLEROSIS (ELSA) AND VERAPAMIL IN HYPERTENSION AND ATHEROSCLEROSIS STUDY (VHAS): Baseline data from these two ongoing studies have provided evidence of the very high prevalence of carotid lesions among hypertensive patients: the prevalence of plaques (defined as a carotid intimal-medial thickness of > or = 1.3 mm) was 83% in ELSA, while in VHAS, in which plaques were defined as an intimal-medial thickness of > 1.5 mm), the plaque prevalence was 37%. These observations emphasize the importance of evaluating the atherosclerotic action of antihypertensive agents. PLAQUE HYPERTENSION LIPID-LOWERING ITALIAN STUDY (PHYLLIS): This trial is using a factorial design to explore the anti-atherosclerotic action of an angiotensin converting enzyme (ACE) inhibitor (fosinopril) versus a diuretic, and also intends to evaluate the possible benefits of associating antihypertensive therapy with a statin to induce lipid-lowering to prevent the progression of carotid atherosclerosis.
多项正在进行的试验正在研究抗高血压药物对高血压患者的抗动脉粥样硬化作用。一种灵敏的定量B型超声技术正在探索颈动脉内膜中层厚度和动脉粥样硬化斑块的变化。多中心伊拉地平/利尿剂动脉粥样硬化研究(MIDAS):这项开创性研究的结果表明,至少在最初6个月内,接受伊拉地平治疗的患者颈动脉斑块进展比接受利尿剂治疗的患者慢。MIDAS在提供高血压患者内膜中层厚度生长速率以及颈动脉超声试验中最佳终点信息方面特别有价值。欧洲拉西地平动脉粥样硬化研究(ELSA)和维拉帕米高血压与动脉粥样硬化研究(VHAS):这两项正在进行的研究的基线数据提供了证据,证明高血压患者中颈动脉病变的患病率非常高:在ELSA中,斑块(定义为颈动脉内膜中层厚度≥1.3毫米)的患病率为83%,而在VHAS中,斑块定义为内膜中层厚度>1.5毫米,斑块患病率为37%。这些观察结果强调了评估抗高血压药物动脉粥样硬化作用的重要性。斑块高血压降脂意大利研究(PHYLLIS):该试验采用析因设计来探索血管紧张素转换酶(ACE)抑制剂(福辛普利)与利尿剂的抗动脉粥样硬化作用,还打算评估将抗高血压治疗与他汀类药物联合使用以诱导降脂预防颈动脉粥样硬化进展的可能益处。